<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Role of inhaled glucocorticoid therapy in stable COPD
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Role of inhaled glucocorticoid therapy in stable COPD
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Role of inhaled glucocorticoid therapy in stable COPD
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James K Stoller, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Barnes, DM, DSc, FRCP, FRS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder that is characterized by both airway and systemic inflammation [
         <a href="#rid1">
          1
         </a>
         ]. Inhaled glucocorticoid (also called inhaled corticosteroid or ICS) therapy appears to reduce this inflammation [
         <a href="#rid2">
          2-6
         </a>
         ]. Thus, it has been hypothesized that ICS therapy may also improve clinical outcomes.
        </p>
        <p>
         Clinical evidence that ICS therapy is beneficial to most patients with COPD is limited. Despite this, 40 to 50 percent of patients with COPD receive ICS therapy [
         <a href="#rid7">
          7,8
         </a>
         ]. Among the reasons for widespread use of ICS therapy are the recognition that COPD can have an asthmatic component and trials demonstrating the benefit of ICS in addition to dual bronchodilator therapy in patients with moderate to severe COPD and frequent exacerbations [
         <a href="#rid9">
          9,10
         </a>
         ]. However, inappropriate use of ICS as part of initial therapy is also common [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         In this topic review, the clinical efficacy of and approach to ICS therapy in patients with COPD are discussed. The adverse effects of inhaled glucocorticoids are discussed in more detail separately. The pharmacologic management of stable COPD and the role of systemic glucocorticoids in COPD exacerbations are also presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">
          "COPD exacerbations: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL EFFICACY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many studies have examined the impact of inhaled glucocorticoids (ICS) on lung function, respiratory symptoms, exacerbations, mortality, lung cancer, and airway inflammation in patients with COPD. These studies have reported conflicting data for several different outcomes. However, taken together, the data suggest that ICS therapy has minimal impact on lung function, but decreases exacerbations, modestly slows the progression of respiratory symptoms, and may marginally improve COPD mortality.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Lung function
         </span>
         <span class="headingEndMark">
          —
         </span>
         The impact of ICS therapy on disease progression, as measured by the annual rate of decline of forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ), has been examined in several randomized trials and three meta-analyses [
         <a href="#rid12">
          12-19
         </a>
         ]. The largest randomized trial [
         <a href="#rid20">
          20
         </a>
         ] and a meta-analysis found that ICS therapy slightly slowed the decline in lung function, whereas several other studies and a different meta-analysis found no beneficial effect on lung function. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TORCH trial – The Toward a Revolution in COPD Health (TORCH) trial randomly assigned 6112 patients with moderate to severe COPD – mean FEV
         <sub>
          1
         </sub>
         was 44 percent of predicted – to one of four treatment arms for three years:
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          salmeterol
         </a>
         alone (50 mcg twice daily),
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         alone (500 mcg twice daily), combination therapy (salmeterol plus fluticasone), or placebo [
         <a href="#rid16">
          16,20
         </a>
         ]. All active treatments slowed the lung function decline compared with placebo, including fluticasone (-55 versus -42 mL per year). The clinical importance of this small difference is unknown.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of trials longer than two years that included the TORCH trial, the mean difference in the rate of decline in postbronchodilator FEV
         <sub>
          1
         </sub>
         between ICS and placebo was 7.3 mL/year (95% CI 3.2-11.4 mL/year, 12,502 participants) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The reason for the conflicting data is uncertain but may be a function of different doses and formulations of inhaled glucocorticoids, length of study, or other confounding factors that influence studies over longer periods of time.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory symptoms were predetermined secondary outcomes in four out of the five randomized trials and one of the meta-analyses [
         <a href="#rid12">
          12,14-16,19
         </a>
         ]. Most demonstrated that ICS therapy slowed the progression of respiratory symptoms modestly [
         <a href="#rid14">
          14-16
         </a>
         ], although one trial found that ICS therapy had no impact on respiratory symptoms [
         <a href="#rid12">
          12
         </a>
         ]. ICS slowed the rate of decline in quality of life compared with placebo, as measured by a standard respiratory disease questionnaire, although the mean difference was not clinically meaningful [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Exacerbations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoid-responsive inflammatory factors appear to play an important role in the initiation and severity of exacerbations of COPD. Thus, it has been hypothesized that ICS therapy may prevent or reduce the severity of COPD exacerbations. Many studies support this theory [
         <a href="#rid9">
          9,10,14-16,19,21-25
         </a>
         ], as illustrated by the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A systematic review and meta-analysis demonstrated that ICS therapy decreased the relative risk of exacerbations compared with placebo (rate ratio 0.88; 95% CI, 0.82-0.94, 10,097 participants); most patients were on background single-agent bronchodilator therapy [
         <a href="#rid19">
          19
         </a>
         ]. Three other meta-analyses reported similar results [
         <a href="#rid21">
          21,23,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The TORCH trial (n = 6112) described above demonstrated that ICS therapy decreased the rate of moderate or severe exacerbations (rate ratio [RR] 0.82; 95% CI, 0.76-0.89) and the rate of exacerbations requiring systemic glucocorticoids (RR 0.65; 95% CI, 0.58-0.73) compared with placebo [
         <a href="#rid16">
          16
         </a>
         ]. However, it did not reduce the rate of severe exacerbations that required hospitalization and its statistical methods have been criticized [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The IMPACT, ETHOS, and TRIBUTE trials each compared a single, once-daily inhaler containing inhaled glucocorticoids, a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) with a combined LABA-LAMA inhaler and other therapies. The annualized rate of moderate to severe exacerbations in the ICS-LAMA-LABA group was lower than with LAMA-LABA alone in each of the three trials (with an absolute improvement ranging from approximately 0.1 to 0.3 per year, RR approximately 0.80). In IMPACT, hospitalizations due to exacerbations were also less frequent (0.13 versus 0.19 per year, RR 0.66). (See
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Exacerbations on LAMA-LABA therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Post-hoc analyses of these and other trials reveal some evidence that the benefits of inhaled glucocorticoids accrue to patients with higher rather than lower markers of eosinophilic inflammation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one post-hoc analysis of three trials of
         <a class="drug drug_general" data-topicid="8524" href="/z/d/drug information/8524.html" rel="external">
          budesonide-formoterol
         </a>
         versus
         <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">
          formoterol
         </a>
         alone (n = 4528), the presence of eosinophils was associated with decreased exacerbations in the budesonide-formoterol group [
         <a href="#rid27">
          27
         </a>
         ]. Patients with eosinophils &gt;100 cells/microL experienced a 25 percent relative risk reduction compared with patients with fewer than 100 eosinophils/microL; the risk reduction was 50 percent for those with eosinophils &gt;340 cells/microL. Similar results were seen with
         <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">
          beclomethasone
         </a>
         in the FORWARD study [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood eosinophil count appeared similarly important in inhaled glucocorticoid efficacy in post-hoc analyses of trials assessing inhaled ICS-LAMA-LABA combined inhaler therapy [
         <a href="#rid29">
          29-32
         </a>
         ]. For example, in IMPACT, the relative rate reduction in moderate to severe exacerbations with ICS-LAMA-LABA compared with LABA-LAMA alone was 0.88 in patients with a blood eosinophil count &lt;90 cells/microL compared with 0.56 in patients with a blood eosinophil count &gt;310 cells/microL [
         <a href="#rid31">
          31
         </a>
         ]. Improvements in lung function by FEV
         <sub>
          1
         </sub>
         were similarly eosinophil-dependent in other large trials of triple inhaler therapy (KRONOS and ETHOS) [
         <a href="#rid30">
          30,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Despite the benefits of inhaled glucocorticoids for patients with moderate to severe COPD, there is also evidence that withdrawal of inhaled glucocorticoids is reasonable in many patients. In the Withdrawal of Inhaled Steroids During Optimized bronchodilator Management (WISDOM) trial, 2485 patients with moderate or severe COPD were treated with triple therapy (
         <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">
          tiotropium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">
          salmeterol
         </a>
         , and
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         , 500 mcg twice daily) for six weeks and then randomly assigned to withdraw fluticasone over 12 weeks or continue triple therapy with ongoing follow-up for 12 months [
         <a href="#rid33">
          33
         </a>
         ]. Comparing withdrawal of ICS with continuation, the hazard ratio (HR) of a first moderate or severe exacerbation of COPD was 1.06 (95% CI 0.94-1.19). Withdrawal was also associated with a small decrement (mean 38 mL at 18 weeks) in FEV
         <sub>
          1
         </sub>
         . Similarly, in the DACCORD observational study, clinicians successfully identified 292 patients as good candidates for a switch from LAMA/LABA/ICS to LAMA/LABA [
         <a href="#rid34">
          34
         </a>
         ]. Compared with 675 patients who remained on LAMA/LABA/ICS therapy, fewer patients who switched had exacerbations or worsening in COPD symptoms (33 versus 56 percent).
        </p>
        <p>
         Patients most likely to benefit from inhaled glucocorticoids are those with exacerbations refractory to other inhaled therapies or elevated eosinophil levels; however, a broader subset of patients with COPD are often inappropriately prescribed these agents. The WISDOM trial, along with the availability of newer inhaled bronchodilator treatment options, supports withdrawal of inhaled glucocorticoids in selected COPD patients while monitoring for clinical worsening. (See
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Pharmacologic adjustment based on assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         ICS therapy likely has a modest impact on COPD mortality, with some evidence that this is driven by a subset of patients with severe disease, frequent exacerbations, and increased eosinophilic inflammation. In a meta-analysis of 60 randomized trials including over 100,000 patients, inhaled glucocorticoids resulted in a small mortality benefit compared with nonglucocorticoid-containing regimens (odds ratio [OR] 0.90, 95% CI 0.84-0.97) [
         <a href="#rid35">
          35
         </a>
         ]. Certain subgroups experienced a greater benefit, including patients with blood eosinophil counts &gt;200 cells/microL (OR 0.58) or &gt;2 percent on the differential (OR 0.61) and patients with two or more moderate to severe exacerbations (OR 0.63).
        </p>
        <p>
         As one example of a trial that contributed to this analysis, the IMPACT trial compared ICS-LAMA-LABA therapy (
         <a class="drug drug_general" data-topicid="114898" href="/z/d/drug information/114898.html" rel="external">
          fluticasone furoate-umeclidinium-vilanterol
         </a>
         ) with a once-daily LAMA-LABA inhaler (
         <a class="drug drug_general" data-topicid="91900" href="/z/d/drug information/91900.html" rel="external">
          umeclidinium-vilanterol
         </a>
         ) or a once-daily glucocorticoid-LABA inhaler (
         <a class="drug drug_general" data-topicid="89424" href="/z/d/drug information/89424.html" rel="external">
          fluticasone furoate-vilanterol
         </a>
         ) in 10,355 patients with COPD who were at increased risk of exacerbations due to a combination of disease severity and exacerbation history [
         <a href="#rid9">
          9
         </a>
         ]. After nearly complete collection of records, there were deaths in 2.4 percent of patients in the triple therapy group, 2.6 percent of patients in the LABA-ICS group, and 3.2 percent of patients in the LABA-LAMA group [
         <a href="#rid36">
          36
         </a>
         ]. The hazard ratio for triple therapy versus
         <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">
          umeclidinium
         </a>
         –vilanterol was 0.72 (95% CI, 0.53-0.99). Other large trials included in the meta-analysis, such as TORCH and ETHOS [
         <a href="#rid10">
          10,16
         </a>
         ], showed similar trends towards improved mortality with some ICS-combination therapies [
         <a href="#rid9">
          9,10,36,37
         </a>
         ].
        </p>
        <p>
         In addition to this evidence from randomized trials, one population-based cohort study compared 5594 new users of a combination ICS-LABA with 2129 new users of a LABA alone [
         <a href="#rid38">
          38
         </a>
         ]. All users were age 66 years or older and met a case definition of COPD. New use of LABAs and ICS was associated with a slightly reduced risk of death compared with new use of LABAs alone (HR 0.92, 95% CI 0.87-0.97).
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Lung cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conflicting data have been presented about whether ICS protects against lung cancer in patients with COPD. While observational studies suggested a protective effect [
         <a href="#rid39">
          39,40
         </a>
         ], a systematic review identified four randomized trials (10,200 participants with COPD) that found no significant effect on lung cancer risk [
         <a href="#rid13">
          13,15,16,41,42
         </a>
         ]. Methodologic issues, such as dose, duration, and adherence to ICS treatment and low rates of lung cancer, limit the conclusions that can be made, but data do not support use of ICS to reduce lung cancer risk in COPD.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhaled glucocorticoid therapy has a few well-described adverse effects in patients with chronic obstructive pulmonary disease (COPD). They include dysphonia, skin bruising, and oral candidiasis [
         <a href="#rid13">
          13,15,43
         </a>
         ]. In general, these effects have not been severe enough to alter management but appear to increase at higher doses and with cumulative exposure. There is also accumulating data for an increased risk of lung infection in patients receiving ICS therapy [
         <a href="#rid9">
          9,10
         </a>
         ]. Additional adverse effects, such as subcapsular cataracts, diminished bone density, and hypothalamic-pituitary-adrenal axis suppression, are suspected, but data are conflicting, or the occurrence is less common. A more detailed discussion of adverse effects associated with inhaled glucocorticoids is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/540.html" rel="external">
          "Major side effects of inhaled glucocorticoids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          GENERAL APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacologic therapy for stable COPD is based on a stepwise approach in which inhaled bronchodilators (beta agonists and muscarinic antagonists) are given alone, in combination, or with the addition of inhaled glucocorticoids (ICS)  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         ). The goals of this approach are to control symptoms, decrease exacerbations, and improve patient function and quality of life. ICS therapy is
         <strong>
          not
         </strong>
         recommended as monotherapy for patients with stable COPD, because inhaled bronchodilators have greater benefits with fewer adverse effects. COPD patients being considered for treatment with inhaled glucocorticoids will usually have moderate to severe airflow obstruction. (See
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management"
         </a>
         .)
        </p>
        <p>
         Nonpharmacologic therapies (eg, smoking cessation, pulmonary rehabilitation, vaccination, nutrition) should be initiated along with pharmacotherapy. (See
         <a class="medical medical_review" href="/z/d/html/120326.html" rel="external">
          "Stable COPD: Overview of management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H163904167">
         <span class="h2">
          Patient selection
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Addition of ICS based on symptoms and exacerbations
         </strong>
         – ICS therapy is indicated as an additional therapy for patients with COPD who have symptoms, repeated exacerbations, or severe exacerbations despite an optimal inhaled bronchodilator regimen, typically a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA). This is based on the observation that for patients with moderate to very severe COPD, triple therapy (LAMA-LABA-ICS) decreases exacerbations compared with dual therapy without an ICS [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Addition of ICS based on blood eosinophils
         </strong>
         – For patients using a single bronchodilator who have one COPD exacerbation a year and a blood eosinophil count ≥300 cells/microL, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy suggests consideration of LAMA-LABA-ICS combination as an alternative to a LAMA-LABA combination  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid44">
          44
         </a>
         ]. Conversely, lower levels of blood eosinophils (eg, &lt;100 cells/microL) predict a low likelihood of response to ICS. For patients with frequent exacerbations of COPD despite combined LAMA-LABA and blood eosinophils ≥100 cells/microL, the GOLD strategy recommends changing to triple therapy with LAMA-LABA-ICS, which is associated with a reduced rate of exacerbations  (
         <a class="graphic graphic_table graphicRef122795" href="/z/d/graphic/122795.html" rel="external">
          table 1
         </a>
         ). Patients with frequent exacerbations despite LAMA-LABA therapy and eosinophils &lt;100 cells/microL may benefit from alternative therapies, typically
         <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">
          roflumilast
         </a>
         or
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         . The studies in support of this approach are described separately. (See
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management", section on 'Group E patients presenting with elevated eosinophil counts or hospitalization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Blood eosinophils, inhaled corticosteroids, and exacerbations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Exacerbations on LAMA-LABA therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asthma and COPD overlap
         </strong>
         – An inhaled glucocorticoid may be warranted earlier (ie, at the same time that the long-acting inhaled bronchodilator is initiated) if there are signs of an asthmatic component to the COPD. (See
         <a class="medical medical_review" href="/z/d/html/122856.html" rel="external">
          "Asthma and COPD overlap (ACO)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal formulation, dose, and schedule of ICS for COPD are unknown. Several of the large clinical trials evaluating the impact of ICS in patients with COPD have used relatively high doses of ICS, including
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         at 400 mcg twice daily or
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         at 500 mcg twice daily [
         <a href="#rid13">
          13,14,16
         </a>
         ]. Although small clinical benefits were achieved at these doses, adverse systemic effects were also detected (eg, cataracts, possible pneumonia) [
         <a href="#rid16">
          16,45
         </a>
         ]. Subsequent trials, such as ETHOS and IMPACT, demonstrated benefit when a moderate ICS dose (eg, budesonide 160 mcg and 320 mcg twice daily; fluticasone furoate 100 mcg once daily) was added to dual bronchodilator therapy [
         <a href="#rid9">
          9,10
         </a>
         ]. In our practice, we use moderate doses of ICS unless the patient has asthma and COPD overlap or, conversely, risk factors for adverse effects; we increase the dose of ICS if needed in patients who continue to have exacerbations.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Systemic glucocorticoid response not predictive of ICS response
         </span>
         <span class="headingEndMark">
          —
         </span>
         It has been hypothesized that patients with COPD who respond favorably to a course of systemic glucocorticoids are more likely to benefit from ICS therapy. There is little evidence to support this theory; thus, selection of patients based on their response to a trial of systemic glucocorticoid therapy is not recommended.
        </p>
        <p class="headingAnchor" id="H282006239">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">
          "Society guideline links: Chronic obstructive pulmonary disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/115180.html" rel="external">
          "Patient education: Inhaled corticosteroid medicines (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4649.html" rel="external">
          "Patient education: Chronic obstructive pulmonary disease (COPD) (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4647.html" rel="external">
          "Patient education: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of inhaled glucocorticoids in COPD
         </strong>
         – In patients with chronic obstructive pulmonary disease (COPD), inhaled glucocorticoids (also known as inhaled corticosteroids or ICS) have minimal impact on lung function, but decrease exacerbations, modestly slow the progression of respiratory symptoms, and may mildly improve COPD mortality. (See
         <a class="local">
          'Clinical efficacy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects of inhaled glucocorticoids
         </strong>
         – Adverse effects of ICS therapy include dysphonia, skin bruising, and oral candidiasis. These adverse effects appear to be more common at higher doses. In addition, ICS therapy may increase the incidence of pneumonia, increase the incidence of cataracts, and diminish bone density. (See
         <a class="local">
          'Adverse effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhaled glucocorticoids as a component of stepwise therapy
         </strong>
         – Pharmacologic therapy for stable COPD is based on a stepwise approach in which inhaled bronchodilators (beta agonists and muscarinic antagonists) are given alone, in combination, or with the addition of ICS  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef122795" href="/z/d/graphic/122795.html" rel="external">
          table 1
         </a>
         ). The goals of this approach are to control symptoms, decrease exacerbations, and improve patient function and quality of life. (See
         <a class="local">
          'General approach'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">
          "Stable COPD: Initial pharmacologic management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential indications for ICS
         </strong>
         – Patients who have persistent symptoms, repeated exacerbations, or severe exacerbations despite a dual long-acting inhaled bronchodilator regimen are good candidates for the addition of ICS therapy. (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of peripheral eosinophils to guide ICS initiation
         </strong>
         – Analysis of multiple trials including ICS therapy in COPD suggest that efficacy shows good correlation to the degree of peripheral eosinophilia. For both initiation and follow-up therapy, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy suggests peripheral eosinophil thresholds of ≥300 cells/microL and &lt;100 cells/microL to delineate patients likely to benefit and unlikely to benefit, respectively, from the addition of ICS to dual bronchodilator (LAMA-LABA) therapy  (
         <a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef122795" href="/z/d/graphic/122795.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Patient selection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">
          "Stable COPD: Follow-up pharmacologic management", section on 'Blood eosinophils, inhaled corticosteroids, and exacerbations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asthma and COPD
         </strong>
         – Inhaled glucocorticoid therapy may be warranted earlier (ie, at the same time that the long-acting inhaled bronchodilator is initiated) if there are signs of an asthmatic component to the COPD. (See
         <a class="local">
          'General approach'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/122856.html" rel="external">
          "Asthma and COPD overlap (ACO)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3281051958">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Marcia Erbland, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sin DD, Paul Man SF. Cooling the fire within: inhaled corticosteroids and cardiovascular mortality in COPD. Chest 2006; 130:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto-Plata VM, Müllerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozol D, Aysan T, Solak ZA, et al. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 2005; 99:1494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Andel AE, Reisner C, Menjoge SS, Witek TJ. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Chest 1999; 115:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 2018; 378:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med 2020; 383:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duan KI, Donovan LM, Spece LJ, et al. Trends and Rural-Urban Differences in the Initial Prescription of Low-Value Inhaled Corticosteroids among U.S. Veterans with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2023; 20:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lung Health Study Research Group, Wise R, Connett J, et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003; 138:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang IA, Ferry OR, Clarke MS, et al. Inhaled corticosteroids versus placebo  for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2023; 3:CD002991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006; 4:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest 2006; 130:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest 2010; 137:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018; 6:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqui SH, Guasconi A, Vestbo J, et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2015; 192:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabe KF, Martinez FJ, Singh D, et al. Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. Ther Adv Respir Dis 2021; 15:17534666211034329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med 2019; 7:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018; 6:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelmeier CF, Worth H, Buhl R, et al. Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study. Respir Res 2022; 23:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Deng ZX, Sun J, et al. Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD: A Meta-analysis of 60 Randomized Controlled Trials. Chest 2023; 163:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipson DA, Crim C, Criner GJ, et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2020; 201:1508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med 2021; 203:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014; 312:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiri VA, Fabbri LM, Davis KJ, Soriano JB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med 2009; 103:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raymakers AJ, McCormick N, Marra CA, et al. Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review. Respirology 2017; 22:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68:1975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selroos O, Backman R, Forsén KO, et al. Local side-effects during 4-year treatment with inhaled corticosteroids--a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy 1994; 49:888.
          </a>
         </li>
         <li class="breakAll">
          Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337:8.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1449 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16963650" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cooling the fire within: inhaled corticosteroids and cardiovascular mortality in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16143583" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : C-reactive protein in patients with COPD, control smokers and non-smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15707484" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15946834" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15229100" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17301099" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10379017" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10084479" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29668352" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32579807" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36867427" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Trends and Rural-Urban Differences in the Initial Prescription of Low-Value Inhaled Corticosteroids among U.S. Veterans with Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10359405" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10379018" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807619" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136260" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17314337" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12809453" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14586043" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36971693" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18511702" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12106623" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17310045" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16735528" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16963657" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Inhaled corticosteroids and mortality in COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19783669" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16439716" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29331313" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26051430" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29429593" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34428980" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31281061" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30232048" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25196117" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35501806" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35921883" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD: A Meta-analysis of 60 Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32162970" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33252985" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25226477" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Combination long-actingβ-agonists and inhaled corticosteroids compared with long-actingβ-agonists alone in older adults with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17185647" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18793832" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27761973" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18778120" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7710001" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Local side-effects during 4-year treatment with inhaled corticosteroids--a comparison between pressurized metered-dose inhalers and Turbuhaler.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7710001" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Local side-effects during 4-year treatment with inhaled corticosteroids--a comparison between pressurized metered-dose inhalers and Turbuhaler.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9203425" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Use of inhaled corticosteroids and the risk of cataracts.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
